Patents by Inventor Chandrasekar Venkataramani

Chandrasekar Venkataramani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATES
    Publication number: 20220409736
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 29, 2022
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • MCL-1 INHIBITORS
    Publication number: 20220340535
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: February 9, 2021
    Publication date: October 27, 2022
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Inhibitors of protein kinases
    Patent number: 11414410
    Abstract: The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: August 16, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
  • LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20210380561
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: May 13, 2021
    Publication date: December 9, 2021
    Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
  • PD-1/PD-L1 INHIBITORS
    Publication number: 20210323922
    Abstract: Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Application
    Filed: November 13, 2020
    Publication date: October 21, 2021
    Applicant: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Todd Appleby, Aesop Cho, Zhimin Du, Michael Graupe, Juan A. Guerrero, Salman Y. Jabri, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Gregory Notte, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • MCL1 INHIBITORS
    Publication number: 20210171543
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 10, 2021
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20210171500
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: November 12, 2020
    Publication date: June 10, 2021
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • MCL-1 inhibitors
    Patent number: 10988451
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: April 27, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • MCL-1 INHIBITORS
    Publication number: 20200331870
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 22, 2020
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20200239458
    Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: November 26, 2019
    Publication date: July 30, 2020
    Inventors: SHAWN M. BAUER, ZHAOZHONG J. JIA, MUKUND MEHROTRA, YONGHONG SONG, QING XU, WOLIN HUANG, CHANDRASEKAR VENKATARAMANI, JACK W. ROSE, ANJALI PANDEY
  • MCL-1 inhibitors
    Patent number: 10703733
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: July 7, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Inhibitors of protein kinases
    Patent number: 10533001
    Abstract: The present invention is directed to topical pharmaceutical compositions of Formula (If) or pharmaceutically acceptable salt thereof, which act as inhibitors of syk and/or JAK kinase activity. The described topical pharmaceutical compositions are useful in preventing or treating a number of conditions mediated at least in part by syk and/or JAK kinase activity.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 14, 2020
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
  • Compounds for the treatment of addiction
    Patent number: 10507215
    Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: December 17, 2019
    Assignee: Amygdala Neurosciences, Inc.
    Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
  • MCL-1 INHIBITORS
    Publication number: 20190352271
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 21, 2019
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Tank-binding kinase inhibitor compounds
    Patent number: 10316049
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 11, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, David Dornan, Juan A. Guerrero, Joshua A. Kaplan, John E. Knox, Devan Naduthambi, Barton W. Phillips, Susanna Y. Stinson, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins
  • Tank-binding kinase inhibitor compounds
    Patent number: 10259811
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: April 16, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Juan Arnaldo Guerrero, Joshua Aaron Kaplan, John Edward Knox, Jr., Devan Naduthambi, Barton W. Phillips, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jeff Zablocki
  • Tank-binding kinase inhibitor compounds
    Patent number: 10253019
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: April 9, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Juan A. Guerrero, Joshua A. Kaplan, John E. Knox, Jr., Jennifer R. Lo, Scott A. Mitchell, Devan Naduthambi, Barton W. Phillips, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Zhongdong Zhao
  • TANK-BINDING KINASE INHIBITOR COMPOUNDS
    Publication number: 20190016717
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Application
    Filed: July 24, 2018
    Publication date: January 17, 2019
    Inventors: Zhimin DU, Juan Arnaldo GUERRERO, Joshua Aaron KAPLAN, John Edward KNOX, JR., Devan NADUTHAMBI, Barton W. PHILLIPS, Chandrasekar VENKATARAMANI, Peiyuan WANG, William J. WATKINS, Jeff ZABLOCKI
  • TANK-BINDING KINASE INHIBITOR COMPOUNDS
    Publication number: 20180370955
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Application
    Filed: June 27, 2018
    Publication date: December 27, 2018
    Inventors: Zhimin DU, Juan A. GUERRERO, Joshua A. KAPLAN, John E. KNOX, JR., Jennifer R. LO, Scott A. MITCHELL, Devan NADUTHAMBI, Barton W. PHILLIPS, Chandrasekar VENKATARAMANI, Peiyuan WANG, William J. WATKINS, Zhongdong ZHAO
  • COMPOUNDS FOR THE TREATMENT OF ADDICTION
    Publication number: 20180338989
    Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 29, 2018
    Applicant: Amygdala Neurosciences, Inc.
    Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki